KLK3 and Familial prostate cancer: Decrease in PSA ≥50% of baseline from trial and prolongation of PSADT resulting from therapy was defined as a clinically significant effect of grape skin phenols as a treatment and would allow delaying androgen deprivation hormonal therapy in men with BRC prostate cancer.